Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

Unexplained kidney disease affecting rural workers across Central America, PRI's 'The World' reports

PRI's "The World" reports on an epidemic of an unexplained kidney disease that is affecting rural workers across Central America, writing, "[I]t's the second biggest cause of death among men in El Salvador, and in Nicaragua it's a bigger killer of men than HIV and diabetes combined," and "the latest theory is that the victims are literally working themselves to death."

14 Dec 2011

Reata, Abbott partner to develop and commercialize AIMs for chronic diseases

Abbott and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators.

12 Dec 2011

Burned military casualties with AKI may have adverse outcomes

Acute kidney injury (AKI), an abrupt or rapid decline in kidney function, is a serious and increasingly prevalent condition. Little information has been available about how common or how severe AKI is in military personnel who are injured during combat in Iraq and Afghanistan. A new study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN) investigates this question in those burned during combat.

12 Dec 2011

ACE inhibitors, ARBs have different effects on heart health of dialysis patients

Two seemingly similar blood pressure-lowering drugs have different effects on the heart health of dialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

12 Dec 2011

Most patients with AKI do not see kidney specialists within a year

Most patients with an abrupt kidney injury that does not get better do not see a kidney specialist within a year, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

12 Dec 2011

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

ChemoCentryx, Inc. today announced the initiation of a Phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease.

9 Dec 2011

FDA advisory panel OKs anemia drug peginesatide

Once approved by the FDA, the once-monthly injection could capture a share of the $3 billion U.S. market for anemia drugs used for kidney dialysis patients, currently dominated by Amgen Inc's blockbuster Epogen. Affymax, which developed the drug with partner Takeda Pharmaceutical Co Ltd, is also expected to price its product below Epogen.

8 Dec 2011

Relaxin improves poor blood flow and kidney function in a rat model of PKD

After a four-week course of the vasodilator hormone relaxin, kidney function and blood flow immediately improved in lab rats genetically altered to model polycystic kidney disease (PKD), a life-threatening genetic disorder, according to research presented on Dec. 6 at the American Society for Cell Biology Annual Meeting in Denver.

7 Dec 2011

Mayo Clinic in Florida now offers kidney and pancreas transplants for HIV-positive patients

Mayo Clinic in Florida is now offering kidney and pancreas transplants to HIV positive patients with advanced kidney disease and diabetes. Evidence is now solid that HIV-positive patients have the same favorable outcome in terms of patient and allograft survival as non-HIV positive organ transplant recipients, says Mary Prendergast, M.D., a kidney specialist whose focus is the care of patients who receive kidney and pancreas transplants.

7 Dec 2011

Researchers reveal how podocytes may regenerate themselves during normal kidney function

Damage to podocytes -- a specialized type of epithelial cell in the kidney -- occurs in more than 90 percent of all chronic kidney disease. Now researchers at the Stanford University School of Medicine have uncovered an unexpected pathway that reveals for the first time how these cells may regenerate and renew themselves during normal kidney function.

6 Dec 2011

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).

5 Dec 2011

Potential test to diagnose membranous nephropathy in early stages

Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) has led to the development of a test that can help diagnose membranous nephropathy in its early stages.

1 Dec 2011

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

GPS at WUSTL now offers new cancer genetic test

Physicians can now take advantage of a new genetics test -- one of the first of its kind to be offered in the United States -- that can help determine the best treatment for cancer patients.

23 Nov 2011

Study evaluates safety and effectiveness of Diamondback device for heart attacks

Drilling through concrete to create an opening may sound more like construction than medicine, but the approach is similar to what researchers at Orlando Regional Medical Center (ORMC) are doing in a clinical trial to evaluate a device that breaks through hardened coronary arteries, in an effort to prevent heart attacks and relieve chest pain.

23 Nov 2011

Diaverum signs joint venture agreement with Nazer Group

November 2011: Diaverum, one of the world´s largest independent renal care providers, has signed a joint venture agreement with Nazer Group, a Saudi Arabian Holding Company with major investments in the medical sector including Bupa Arabia.

22 Nov 2011

New blood spot analysis method can diagnose range of clinical conditions

Scientists have developed a rapid method that can be used to simultaneously screen patients for a range of genetic and acquired clinical conditions from a single dried blood spot.

17 Nov 2011

Mycophenolate mofetil superior to azathioprine for lupus nephritis

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.

17 Nov 2011

New non-invasive measurement may predict people at risk of heart failure

A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania and collaborators at various institutions, presented at the 2011 American Heart Association Scientific Sessions, shows that a novel, non-invasive measurement of arterial wave reflections may be able to predict who is most at risk for heart failure.

15 Nov 2011

Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012

Concert Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial of CTP-499, a novel agent for the potential treatment of diabetic nephropathy.

14 Nov 2011